|
gptkbp:instanceOf
|
genetic engineering technology
prokaryotic immune system
|
|
gptkbp:alternativeTo
|
gptkb:TALEN
gptkb:ZFN
meganucleases
|
|
gptkbp:application
|
biomedical research
disease resistance
diagnostics
functional genomics
crop improvement
antiviral defense
|
|
gptkbp:component
|
gptkb:Cas_proteins
CRISPR sequences
|
|
gptkbp:controversy
|
ethical concerns
germline editing
intellectual property disputes
gene editing in humans
|
|
gptkbp:discoveredBy
|
gptkb:Emmanuelle_Charpentier
gptkb:Jennifer_Doudna
gptkb:Francisco_Mojica
|
|
gptkbp:firstDescribed
|
2005
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CRISPR-Cas systems
|
|
gptkbp:introducedIn
|
gptkb:Bacteria
gptkb:Streptococcus_pyogenes
|
|
gptkbp:mechanismOfAction
|
targeted DNA cleavage
RNA-guided endonuclease activity
adaptive immunity in bacteria and archaea
|
|
gptkbp:NobelPrizeYear
|
gptkb:2020_Nobel_Prize_in_Chemistry
|
|
gptkbp:notableGroup
|
gptkb:CRISPR-Cas3
gptkb:CRISPR-Cas12
gptkb:CRISPR-Cas13
gptkb:CRISPR-Cas9
|
|
gptkbp:patent
|
gptkb:Broad_Institute
gptkb:University_of_California
|
|
gptkbp:publishedIn
|
gptkb:Nature
gptkb:science
Cell
|
|
gptkbp:regulates
|
regulated by EMA (in the EU)
regulated by FDA (in the US)
subject to bioethics laws
|
|
gptkbp:relatedTo
|
gptkb:Bacteria
archaea
phage resistance
adaptive immunity
|
|
gptkbp:usedFor
|
gptkb:agricultural_machinery
genome editing
gene therapy
disease modeling
gene activation
gene knockout
gene repression
|
|
gptkbp:bfsParent
|
gptkb:CRISPR-Cas14
|
|
gptkbp:bfsLayer
|
6
|